ADDERALL 20 Drug Patent Profile

« Back to Dashboard

When do Adderall 20 patents expire, and what generic alternatives are available?

Adderall 20 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 20 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 20

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ADDERALL 20

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-008	Feb 13, 1996		DISCN	Yes	No

International Patents for ADDERALL 20

See the table below for patents covering ADDERALL 20 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6089200
Canada	2378336
European Patent Office	1202739
Japan	2003504406

Last updated: February 13, 2026

What is the current market status of ADDERALL 20?

ADDERALL 20 (amphetamine and dextroamphetamine) is a prescription psychostimulant approved for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. It holds a significant share in the US ADHD medication market, estimated at USD 4.9 billion in 2022, with an annual growth rate of approximately 6.2% since 2018. Despite patent expirations and generic competition, ADDERALL remains a dominant brand owing to its established efficacy and prescriber loyalty.

How does ADDERALL 20 position in the pharmaceutical pipeline?

There are limited reformulations or direct competitors within the same formulation and dosage. However, the market faces competition from extended-release formulations (e.g., Vyvanse, Focalin XR). The main pipeline efforts include novel delivery systems and prodrugs aimed at reducing abuse potential and improving pharmacokinetics. Currently, no new ADDERALL-specific formulations have gained FDA approval nor are under active investigation.

What are the primary patent and regulatory considerations?

ADDERRALL’s primary patent protections expired in 2011 for its formulation, leaving many manufacturers to produce generic versions. The original patent for the brand’s core formulation was filed in 1960. As generics proliferate, the brand's market share depends heavily on prescriber and patient loyalty. The FDA categorizes ADDERALL as a Schedule II controlled substance, imposing strict prescribing and dispensing regulations.

What are the key sales and market dynamics?

Sales are concentrated in North America, especially the US, where healthcare providers widely prescribe ADDERALL for ADHD. Market access depends on insurance coverage, with private payers often favoring generic versions. The rapid growth of generic substitutes has decreased the brand’s premium pricing potential, though it maintains a substantial market due to clinical familiarity.

What R&D efforts influence future investment?

Research focuses on developing abuse-deterrent formulations, extended-release versions, and prodrugs with lower abuse potential. Companies like Evoke Pharma and Teva are working on such formulations, but none have reached the market specifically for ADDERALL 20. No recent patent filings or clinical trials target this specific dosage, limiting near-term pipeline revenue potential.

What is the investment outlook?

Despite patent expirations, ADDERALL maintains stable revenue streams in the short-to-medium term due to brand loyalty, prescriber familiarity, and ongoing demand. The main risk involves regulatory changes, increased generic competition, and potential shifts toward non-stimulant ADHD treatments. Long-term growth prospects hinge on the development of reformulation alternatives with reduced abuse potential and broader indications.

Key market fundamentals and investment risks:

Parameter	Data
US market size (2022)	USD 4.9 billion
CAGR (2018–2022)	6.2%
Patent expiration	2011 (original patents)
FDA approval status	Approved for ADHD and narcolepsy
Abusive potential	High; Schedule II controlled substance
Key competitors	Vyvanse, Focalin XR, Concerta
Pipeline activity	Mainly reformulations and abuse-deterrents

Key takeaways

• ADDERALL 20 remains a valuable asset due to brand loyalty and market dominance despite generic competition.
• Patent expirations have shifted revenue to generics; the brand’s future depends on reformulation and abuse-deterrent strategies.
• Regulatory controls limit prescribing flexibility but also restrict unapproved competition.
• Market growth is driven by increasing ADHD diagnoses, but pricing power diminishes amid product commoditization.
• Investment should monitor pipeline developments and regulatory trends affecting Schedule II stimulants.

FAQs

1. How does the patent landscape affect ADDERALL’s future?
The original patents expired in 2011, leading to widespread generic manufacturing. Future revenues depend on brand strength and potential reformulations rather than proprietary protection.

2. Is there ongoing research to modify ADDERALL’s formulation?
R&D efforts focus on abuse-deterrent and extended-release formulations, but no new ADDERALL 20-specific formulations have received FDA approval to date.

3. How vulnerable is the market to generic competition?
Highly vulnerable; generics account for the majority of sales, limiting the brand’s pricing power.

4. What regulatory challenges do manufacturers face?
Strict control measures on Schedule II substances restrict prescribing and dispensing practices, impacting overall volume and distribution.

5. What is the long-term outlook for ADDERALL 20?
Long-term viability relies on innovations that reduce abuse potential and evolving treatment paradigms that favor non-stimulant options.

References

[1] Market data from IQVIA.
[2] FDA approvals and schedules.
[3] Industry reports on ADHD medication trends.